Differential effects of CTLA-4 substitutions on the binding of human CD80 (B7-1) and CD86 (B7-2)
- PMID: 8557978
Differential effects of CTLA-4 substitutions on the binding of human CD80 (B7-1) and CD86 (B7-2)
Abstract
CTLA-4 expressed on activated T cells binds to CD80 (B7-1) and CD86 (B7-2) molecules present on APC with high avidity and appears to deliver a negative regulatory signal to the T cell. We have investigated the kinetics of CTLA-4 binding to CD80 and CD86, together with the effects of selected CTLA-4 mutations on binding activity. The dissociation constants (Kd) for binding of CTLA-4-Ig to CD80 and CD86 transfectants were 8.1 and 6.7 nM, respectively. Surface plasmon resonance was used to determine kinetic parameters of CTLA-4-Ig binding to CD80-Ig and CD86-Ig fusion proteins and revealed enhanced association (ka) and dissociation (kd) rate constants for CD86-Ig compared with CD80-Ig. Furthermore, CD80-Ig and CD86-Ig fusion molecules demonstrated variable abilities to cross-compete for binding to several modified forms of CTLA-4-Ig. Differential binding of CD80 and CD86 to CTLA-4 was further revealed by analysis of 10 discrete CTLA-4 mutants. Five single amino acid substitutions within the CTLA-4 MYPPPY domain exerted modest effects on CD80 binding, but each of these substitutions completely abrogated CD86 binding. In addition, substitutions just N-terminal of the MYPPPY region, and within the CDR1-like region of CTLA-4, eliminated both CD80 and CD86 binding. Hence, CD80 and CD86 bind with different association/dissociation kinetics to similar, but distinct, sites on CTLA-4.
Similar articles
-
Interactions of CD80 and CD86 with CD28 and CTLA4.J Immunol. 1996 Apr 15;156(8):2700-9. J Immunol. 1996. PMID: 8609386
-
Activation of human peripheral blood dendritic cells induces the CD86 co-stimulatory molecule.Eur J Immunol. 1995 Jul;25(7):2064-8. doi: 10.1002/eji.1830250739. Eur J Immunol. 1995. PMID: 7542604
-
Expression of a hypoglycosylated form of CD86 (B7-2) on human T cells with altered binding properties to CD28 and CTLA-4.J Immunol. 1997 Nov 15;159(10):4799-805. J Immunol. 1997. PMID: 9366404
-
Structural mechanisms of costimulation.Nat Immunol. 2002 May;3(5):427-34. doi: 10.1038/ni0502-427. Nat Immunol. 2002. PMID: 11976720 Review.
-
Molecular interactions mediating T cell antigen recognition.Annu Rev Immunol. 2003;21:659-84. doi: 10.1146/annurev.immunol.21.120601.141036. Epub 2001 Dec 19. Annu Rev Immunol. 2003. PMID: 12615890 Review.
Cited by
-
Role of the CTLA-4 receptor in T cell activation and immunity. Physiologic function of the CTLA-4 receptor.Immunol Res. 1998;18(2):103-15. doi: 10.1007/BF02788753. Immunol Res. 1998. PMID: 9844829 Review.
-
Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.Clin Pharmacokinet. 2013 Feb;52(2):83-124. doi: 10.1007/s40262-012-0027-4. Clin Pharmacokinet. 2013. PMID: 23299465 Review.
-
Molecular basis of cross-species reactivities of human versus porcine CTLA-4.Hum Immunol. 2013 Jul;74(7):842-8. doi: 10.1016/j.humimm.2013.04.002. Epub 2013 Apr 18. Hum Immunol. 2013. PMID: 23602875 Free PMC article.
-
An Activating Janus Kinase-3 Mutation Is Associated with Cytotoxic T Lymphocyte Antigen-4-Dependent Immune Dysregulation Syndrome.Front Immunol. 2017 Dec 15;8:1824. doi: 10.3389/fimmu.2017.01824. eCollection 2017. Front Immunol. 2017. PMID: 29375547 Free PMC article.
-
The modulation of B7.2 and B7.1 on B cells by immunosuppressive agents.Clin Exp Immunol. 1999 Oct;118(1):1-8. doi: 10.1046/j.1365-2249.1999.01028.x. Clin Exp Immunol. 1999. PMID: 10540152 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources